levodopa has been researched along with Cognitive Dysfunction in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (62.50) | 24.3611 |
| 2020's | 9 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Alekseenko, PV; Ismailova, SB; Mosaleva, EI; Pokhabov, DV; Prokopenko, SV; Zhumzhanov, IM | 1 |
| Che, NN; Chen, SY; Li, X; Ma, JJ; Yang, HQ | 1 |
| Belcaro, G; Cesarone, MR; Cotellese, R; Feragalli, B; Hosoi, M; Hu, S; Ledda, A; Maione, C; Scipione, C; Scipione, V | 1 |
| Fukunaga, K; Haga, H; Izumi, H; Kawahata, I; Miyachi, H; Shinoda, Y; Yamada, R | 1 |
| Chen, S; Duan, S; Fang, J; Le, Y; Li, D; Li, F; Qing, W; Tan, L; Tong, J; Wang, Y; Yang, J; Zhang, B | 1 |
| Borghammer, P; Callesen, MB; Damholdt, MF; Kjær, SW; Larsen, L; Østergaard, K | 1 |
| Baschi, R; Cicero, CE; Davì, M; Luca, A; Monastero, R; Mostile, G; Nicoletti, A; Restivo, V; Zappia, M | 1 |
| Awad, N; Roy, D; Song, J; Zamudio, P | 1 |
| Cherian, A; K P, D; Krishnan, S; Paramasivan, NK | 1 |
| Bajaj, N; Barker, RA; Ben-Shlomo, Y; Burn, DJ; Foltynie, T; Grosset, DG; Grosset, KA; Hardy, J; Lawton, MA; Malek, N; Morris, HR; Williams, NM; Wood, N | 1 |
| Foki, T; Hitzl, D; Lehrner, J; Novak, K; Pirker, W; Pusswald, G | 1 |
| Amboni, M; Barone, P; Cesarelli, M; Fasano, A; Iavarone, A; Iuppariello, L; Lista, I; Palladino, R; Picillo, M; Rucco, R; Sorrentino, G; Varriale, P; Vitale, C | 1 |
| Alty, JE; Clissold, BG; Ding, C; Ganga, G; Kempster, PA; McColl, CD; Nagao, K; Reardon, KA; Schiff, M | 1 |
| Gul, A; Yousaf, J | 1 |
| Arnaldi, D; Babiloni, C; Bonanni, L; Buttinelli, C; Catania, V; D'Antonio, F; De Lena, C; De Pandis, MF; Del Percio, C; Emek-Savaş, DD; Famà, F; Farotti, L; Ferri, R; Fraioli, L; Franciotti, R; Frisoni, GB; Fuhr, P; Giubilei, F; Gschwandtner, U; Güntekin, B; Hanoğlu, L; Lizio, R; Lopez, S; McKeith, I; Nobili, F; Noce, G; Onofrj, M; Orzi, F; Parnetti, L; Pascarelli, MT; Pievani, M; Ransmayr, G; Soricelli, A; Stirpe, P; Stocchi, F; Taylor, JP; Triggiani, AI; Vacca, L; Yener, G | 1 |
| Chen, S; Cui, S; Du, JJ; Fu, R; Gao, C; Huang, P; Lin, Y; Wang, T; Zhou, H | 1 |
| Chung, SJ; Lee, HS; Lee, PH; Lee, YH; Sohn, YH; Ye, BS; Yoo, HS | 1 |
| Centonze, D; Fasano, A; Femiano, C; Lena, F; Modugno, N; Olivola, E; Santilli, M; Varanese, S | 1 |
| Cáceres-Redondo, MT; Carballo, M; Carrillo, F; Huertas-Fernández, I; Lama, MJ; Mir, P; Vargas-González, L | 1 |
| Gambini, O; Islam, L; Piacentini, S; Scarone, S; Soliveri, P | 1 |
| Ding, Z; Ge, J; Guo, S; Liu, F; Liu, Z; Tang, Y; Wang, J; Wang, Y; Wu, J; Wu, P; Zuo, C | 1 |
| Carbonetti, R; Giannini, MT; Hoffmann, GF; Leuzzi, V; Mastrangelo, M | 1 |
| Counsell, CE; Davidson, MB; McGhee, DJ | 1 |
| Gomperts, SN; Growdon, JH; Johnson, KA; Locascio, JJ; Marquie, M; Maye, J; Rentz, DM; Santarlasci, AL | 1 |
1 trial(s) available for levodopa and Cognitive Dysfunction
| Article | Year |
|---|---|
[Dynamics of cognitive impairments during L-dopa therapy in Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Cognition; Cognitive Dysfunction; Humans; Levodopa; Mental Status and Dementia Tests; Parkinson Disease | 2021 |
23 other study(ies) available for levodopa and Cognitive Dysfunction
| Article | Year |
|---|---|
Autoimmune-mediated secondary-parkinsonism presented with micrographia and cognitive impairment.
Topics: Adult; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Antiparkinson Agents; Autoantibodies; Benserazide; Cognitive Dysfunction; Drug Combinations; Fever of Unknown Origin; Handwriting; Humans; Immunosuppressive Agents; Immunotherapy; Levodopa; Male; Methylprednisolone; Neuropsychological Tests; Parkinson Disease, Secondary; Tremor | 2021 |
Supplementary management with Pycnogenol® in Parkinson's disease to prevent cognitive impairment.
Topics: Carbidopa; Cognition; Cognitive Dysfunction; Dietary Supplements; Drug Combinations; Female; Free Radicals; Humans; Levodopa; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Registries | 2020 |
Novel fatty acid-binding protein 3 ligand inhibits dopaminergic neuronal death and improves motor and cognitive impairments in Parkinson's disease model mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antiparkinson Agents; Blood-Brain Barrier; Cell Death; Cognitive Dysfunction; Disease Models, Animal; Dopaminergic Neurons; Fatty Acid Binding Protein 3; Levodopa; Ligands; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neuroprotective Agents; Parkinson Disease; Protein Aggregation, Pathological | 2020 |
Small dose of L-dopa/Benserazide hydrochloride improved sepsis-induced neuroinflammation and long-term cognitive dysfunction in sepsis mice.
Topics: Animals; Benserazide; Brain; Cognitive Dysfunction; Disease Models, Animal; Drug Combinations; Hippocampus; Levodopa; Male; Mice; Mice, Inbred C57BL; Neuroimmunomodulation; Receptors, Dopamine D1; Receptors, Dopamine D2; Sepsis; Sepsis-Associated Encephalopathy | 2020 |
Applied strategy in the Iowa Gambling Task: Comparison of individuals with Parkinson's disease to healthy controls.
Topics: Aged; Cognitive Dysfunction; Decision Making; Dopamine Agents; Executive Function; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease | 2020 |
Cognitive impairment and levodopa induced dyskinesia in Parkinson's disease: a longitudinal study from the PACOS cohort.
Topics: Aged; Attention; Cognitive Dysfunction; Cohort Studies; Dyskinesia, Drug-Induced; Executive Function; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Proportional Hazards Models; Severity of Illness Index | 2021 |
Treatment of unexplained coma and hypokinetic-rigid syndrome in a patient with COVID-19.
Topics: Blood Coagulation; Brain Diseases; Carbidopa; Central Nervous System Stimulants; Cognitive Dysfunction; COVID-19; Critical Care; Drug Combinations; Humans; Hypokinesia; Ischemic Stroke; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Modafinil; Rehabilitation; Respiration, Artificial; SARS-CoV-2; Severity of Illness Index; Treatment Outcome; Ventilator Weaning | 2021 |
Pearls & Oy-sters: Levodopa-Responsive Adult NCL (Type B Kufs Disease) Due to
Topics: Adult; Cognitive Dysfunction; Consanguinity; Dopamine Agents; Female; Humans; Levodopa; Membrane Proteins; Mutation, Missense; Neuronal Ceroid-Lipofuscinoses | 2021 |
Utility of the new Movement Disorder Society clinical diagnostic criteria for Parkinson's disease applied retrospectively in a large cohort study of recent onset cases.
Topics: Aged; Brain; Cognitive Dysfunction; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Retrospective Studies; Severity of Illness Index; United Kingdom | 2017 |
Individual cognitive change after DBS-surgery in Parkinson's disease patients using Reliable Change Index Methodology.
Topics: Cognition; Cognitive Dysfunction; Deep Brain Stimulation; Humans; Levodopa; Neuropsychological Tests; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome | 2018 |
Step length predicts executive dysfunction in Parkinson's disease: a 3-year prospective study.
Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Cognitive Dysfunction; Disease Progression; Executive Function; Female; Follow-Up Studies; Gait; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Prognosis; Prospective Studies | 2018 |
Inferring the long duration response to levodopa in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cognitive Dysfunction; Disease Progression; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Severity of Illness Index; Time Factors | 2019 |
Effect of levodopa on frontal-subcortical and posterior cortical functioning in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Cerebral Cortex; Cognition; Cognitive Dysfunction; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease | 2019 |
Levodopa may affect cortical excitability in Parkinson's disease patients with cognitive deficits as revealed by reduced activity of cortical sources of resting state electroencephalographic rhythms.
Topics: Aged; Antiparkinson Agents; Cerebral Cortex; Cognitive Dysfunction; Electroencephalography; Female; Humans; Levodopa; Male; Parkinson Disease; Rest | 2019 |
Clinical characteristics and quality of life in Chinese patients with multiple system atrophy.
Topics: Antiparkinson Agents; Anxiety Disorders; Asian People; China; Cognitive Dysfunction; Depressive Disorder; Female; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Parkinson Disease; Quality of Life | 2018 |
Levodopa-induced dyskinesia is closely linked to progression of frontal dysfunction in PD.
Topics: Aged; Antiparkinson Agents; Cognitive Dysfunction; Cohort Studies; Dementia; Disease Progression; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Retrospective Studies | 2019 |
Continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Carbidopa; Cognitive Dysfunction; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Drug Substitution; Electronic Health Records; Female; Humans; Infusions, Subcutaneous; Levodopa; Male; Medication Adherence; Middle Aged; Parkinson Disease; Retrospective Studies | 2019 |
Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cognition Disorders; Cognitive Dysfunction; Disease Progression; Drug Combinations; Female; Follow-Up Studies; Gastrostomy; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2014 |
Capgras delusion for animals and inanimate objects in Parkinson's Disease: a case report.
Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Capgras Syndrome; Carbidopa; Clozapine; Cognitive Dysfunction; Delusions; Dibenzothiazepines; Dogs; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Parkinson Disease; Pets; Plants; Quetiapine Fumarate | 2015 |
Cerebral Metabolic Differences Associated with Cognitive Impairment in Parkinson's Disease.
Topics: Aged; Brain; Cerebral Cortex; Cognitive Dysfunction; Dementia; Female; Fluorodeoxyglucose F18; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Positron-Emission Tomography | 2016 |
Neuromotor and cognitive outcomes of early treatment in tyrosine hydroxylase deficiency type B.
Topics: Adolescent; Cognitive Dysfunction; Dopamine Agents; Dystonic Disorders; Early Diagnosis; Humans; Levodopa; Male; Motor Skills Disorders; Treatment Outcome | 2017 |
Comparison of patient rated treatment response with measured improvement in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cognitive Dysfunction; Dopamine Agonists; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Patient Satisfaction; Prospective Studies; Treatment Outcome | 2012 |
Brain amyloid and cognition in Lewy body diseases.
Topics: Aged; Amyloid beta-Peptides; Aniline Compounds; Antiparkinson Agents; Apolipoprotein E3; Cognition; Cognitive Dysfunction; Female; Genotype; Humans; Levodopa; Lewy Body Disease; Male; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Positron-Emission Tomography; Thiazoles | 2012 |